By Will Maddox – Fierce Biotech –
After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.
The agreement, announced in Beam’s end-of-year filing, follows Pfizer’s exit from the gene therapy field last February when it discontinued hemophilia product Beqvez less than a year after securing FDA approval.
